Winston C Vaughan, MD
Otolaryngology · Atherton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 3 carriers
- Offices
- 5
Offices
5 locations · Bass Medical Group · 292 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Vaughan’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G77809 · Current
Licensed to practise in California · since 1993 · expires 2027-09-30 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Waverley Surgery Center, LPAmbulatory Surgery Center · Palo Alto, CA1.04% owner since 2015 · accredited by AAAHCAccreditation Renewed4 inspections, 3 with deficiencies · last 2024-04-25
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$475,725
Medicare paid this office $475,725 for 664 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Diagnostic exam of nasal passages using an endoscope | 629 | $265,991 | $180 |
| Short return visit (20+ min) | 522 | $97,352 | $85 |
| Return visit (30+ min) | 223 | $41,506 | $121 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 48 | $21,086 | $289 |
| Ct scan of face without contrast | 78 | $11,562 | $134 |
See all 8 services
| Diagnostic exam of nasal passages using an endoscope | 629 | $265,991 | $180 |
| Short return visit (20+ min) | 522 | $97,352 | $85 |
| Return visit (30+ min) | 223 | $41,506 | $121 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 48 | $21,086 | $289 |
| Ct scan of face without contrast | 78 | $11,562 | $134 |
| New patient visit (45+ min) | 71 | $10,644 | $150 |
| New patient visit (30+ min) | 58 | $5,964 | $103 |
| Removal of impacted ear wax | 11 | $625 | $39 |
Who their Medicare patients are
664 Original Medicare patients in 2024. Average age 76 · Women 58% · Also on Medicaid 2% · Health risk score 0.95. At or below the middle of the specialty; the typical otolaryngology clinician is at 1.19.
Conditions among them: High blood pressure 63% · Coronary heart disease 25% · Diabetes 17% · Atrial fibrillation 17% · Cancer 16% · COPD 16% · Depression 13% · Chronic kidney disease 12% · Heart failure 9% · Stroke 5% · Dementia 2%.
The office billed $1,650,931, Medicare allowed $620,631 and paid $475,725; for 3,317 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 664 | 3,317 | 76 | 0.95 | $1,650,931 | $475,725 |
| 2023 | 623 | 3,234 | 76 | 0.93 | $1,547,249 | $440,907 |
| 2022 | 553 | 3,038 | 76 | 0.89 | $1,443,765 | $416,179 |
| 2021 | 485 | 2,639 | 74 | 0.92 | $1,268,766 | $379,519 |
| 2020 | 495 | 2,384 | 74 | 1.01 | $1,039,818 | $309,051 |
| 2019 | 586 | 3,398 | 73 | 1.02 | $1,461,306 | $452,185 |
| 2018 | 523 | 3,215 | 73 | 0.99 | $1,393,846 | $435,534 |
| 2017 | 508 | 3,248 | 73 | 1.04 | $1,420,876 | $445,725 |
| 2016 | 544 | 3,438 | 73 | 1.02 | $1,721,449 | $477,891 |
| 2015 | 547 | 3,117 | 73 | 0.99 | $1,848,470 | $481,109 |
| 2014 | 507 | 3,088 | 72 | 0.94 | $1,642,677 | $439,070 |
| 2013 | 438 | 2,496 | 72 | 1.00 | $1,214,562 | $353,641 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Diagnostic exam of nasal passages using an endoscope | 592 | $257,149 | $179 |
| Short return visit (20+ min) | 512 | $97,704 | $83 |
| Return visit (30+ min) | 193 | $32,552 | $118 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 45 | $17,787 | $282 |
| Ct scan of face without contrast | 90 | $12,352 | $125 |
| New patient visit (45+ min) | 66 | $9,398 | $142 |
| New patient visit (30+ min) | 51 | $5,284 | $104 |
| Short return visit | 15 | $551 | $34 |
2022: 7 services
| Diagnostic exam of nasal passages using an endoscope | 536 | $248,110 | $181 |
| Short return visit (20+ min) | 477 | $99,152 | $83 |
| Return visit (30+ min) | 121 | $17,641 | $117 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 29 | $11,948 | $314 |
| Ct scan of face without contrast | 88 | $11,368 | $124 |
| New patient visit (45+ min) | 72 | $10,494 | $146 |
| New patient visit (30+ min) | 36 | $3,742 | $104 |
2021: 9 services
| Diagnostic exam of nasal passages using an endoscope | 464 | $221,435 | $190 |
| Short return visit (20+ min) | 396 | $78,743 | $84 |
| Return visit (30+ min) | 169 | $28,017 | $118 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 36 | $15,079 | $296 |
| New patient visit (45+ min) | 67 | $9,736 | $145 |
| Ct scan of face without contrast | 63 | $7,952 | $124 |
| Ct guidance for needle or tube localization | 14 | $3,302 | $236 |
| Removal of nasal sinus tissue using an endoscope | 11 | $2,670 | $223 |
| New patient visit (30+ min) | 18 | $1,892 | $105 |
2020: 9 services
| Diagnostic exam of nasal passages using an endoscope | 461 | $183,576 | $179 |
| Short return visit (20+ min) | 422 | $71,195 | $70 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 24 | $8,777 | $325 |
| Ct scan of face without contrast | 63 | $8,742 | $127 |
| New patient visit (30+ min) | 69 | $6,845 | $99 |
| Return visit (30+ min) | 59 | $6,265 | $103 |
| Removal of nasal sinus tissue using an endoscope | 14 | $3,612 | $258 |
| New patient visit (45+ min) | 23 | $3,349 | $146 |
| Computer-assisted procedure outside membrane covering brain | 13 | $2,024 | $156 |
2019: 8 services
| Diagnostic exam of nasal passages using an endoscope | 536 | $293,019 | $188 |
| Short return visit (20+ min) | 492 | $99,587 | $69 |
| Return visit (30+ min) | 83 | $9,642 | $99 |
| Ct scan of face without contrast | 73 | $9,633 | $128 |
| New patient visit (30+ min) | 97 | $9,577 | $99 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 24 | $7,821 | $301 |
| Removal of nasal sinus tissue using an endoscope | 14 | $3,507 | $234 |
| New patient visit (45+ min) | 22 | $3,009 | $137 |
2018: 8 services
| Diagnostic exam of nasal passages using an endoscope | 499 | $290,280 | $197 |
| Short return visit (20+ min) | 440 | $89,558 | $66 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 30 | $11,221 | $330 |
| Ct scan of face without contrast | 80 | $10,995 | $132 |
| New patient visit (30+ min) | 95 | $9,265 | $98 |
| Return visit (30+ min) | 72 | $8,116 | $98 |
| Removal of nasal sinus tissue using an endoscope | 12 | $2,312 | $193 |
| New patient visit (45+ min) | 12 | $1,504 | $125 |
2017: 8 services
| Diagnostic exam of nasal passages using an endoscope | 476 | $286,225 | $198 |
| Short return visit (20+ min) | 427 | $92,339 | $67 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 34 | $13,736 | $319 |
| Ct scan of face without contrast | 84 | $10,547 | $123 |
| Return visit (30+ min) | 94 | $10,233 | $96 |
| New patient visit (30+ min) | 78 | $7,600 | $97 |
| Removal of nasal sinus tissue using an endoscope | 12 | $2,695 | $225 |
| New patient visit (45+ min) | 15 | $2,226 | $148 |
2016: 8 services
| Diagnostic exam of nasal passages using an endoscope | 521 | $322,398 | $201 |
| Short return visit (20+ min) | 467 | $87,253 | $62 |
| Ct scan of face without contrast | 84 | $12,250 | $132 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 43 | $11,681 | $260 |
| New patient visit (30+ min) | 118 | $10,248 | $87 |
| Exploration of nasal sinus using an endoscope | 14 | $8,618 | $616 |
| Return visit (30+ min) | 39 | $4,398 | $94 |
| Removal of nasal sinus tissue using an endoscope | 19 | $4,251 | $224 |
2015: 10 services
| Diagnostic exam of nasal passages using an endoscope | 529 | $331,142 | $200 |
| Short return visit (20+ min) | 414 | $58,722 | $60 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 54 | $16,662 | $245 |
| Exploration of nasal sinus using an endoscope | 24 | $14,164 | $567 |
| Ct scan of face without contrast | 85 | $11,721 | $129 |
| New patient visit (30+ min) | 112 | $10,318 | $92 |
| Return visit (30+ min) | 59 | $5,868 | $92 |
| Removal of nasal sinus tissue using an endoscope | 19 | $3,645 | $192 |
| Removal of nasal sinus using an endoscope | 15 | $3,407 | $227 |
| Partial removal of nasal sinus using an endoscope | 11 | $1,647 | $137 |
2014: 9 services
| Diagnostic exam of nasal passages using an endoscope | 490 | $275,480 | $200 |
| Short return visit (20+ min) | 405 | $70,283 | $61 |
| Ct scan of face without contrast | 110 | $20,800 | $175 |
| New patient visit (30+ min) | 131 | $12,033 | $92 |
| Return visit (30+ min) | 104 | $11,842 | $88 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 39 | $10,820 | $252 |
| Exploration of nasal sinus using an endoscope | 19 | $10,719 | $564 |
| Removal of nasal sinus tissue using an endoscope | 18 | $4,318 | $227 |
| Removal of nasal sinus using an endoscope | 12 | $2,898 | $241 |
2013: 10 services
| Diagnostic exam of nasal passages using an endoscope | 424 | $222,896 | $205 |
| Short return visit (20+ min) | 370 | $54,978 | $59 |
| Ct scan of face without contrast | 88 | $20,693 | $223 |
| New patient visit (30+ min) | 108 | $9,982 | $92 |
| Exploration of nasal sinus using an endoscope | 16 | $9,385 | $587 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 25 | $9,309 | $321 |
| Return visit (30+ min) | 75 | $8,057 | $89 |
| Removal of nasal sinus tissue using an endoscope | 15 | $3,254 | $217 |
| Removal of nasal sinus using an endoscope | 12 | $2,929 | $244 |
| Computer-assisted procedure outside membrane covering brain | 18 | $2,887 | $160 |
Drugs they prescribed that Part D paid
$43,955
Pharmacies billed $43,955 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
483 generic and fewer than 11 brand-name prescriptions · $43,955 in drug cost · 192 antibiotic prescriptions to 132 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ipratropium | 52 | $1,628 | $31 |
| Azelastine | 21 | $729 | $35 |
| Doxycycline Hyclate | 50 | $565 | $11 |
| Methylprednisolone | 55 | $387 | $7 |
| Ciprofloxacin | 34 | $373 | $11 |
See all 13 drugs
| Ipratropium | 52 | $1,628 | $31 |
| Azelastine | 21 | $729 | $35 |
| Doxycycline Hyclate | 50 | $565 | $11 |
| Methylprednisolone | 55 | $387 | $7 |
| Ciprofloxacin | 34 | $373 | $11 |
| Amoxicillin-Clavulanate Potass | 41 | $330 | $8 |
| Azithromycin | 27 | $237 | $9 |
| Prednisone | 38 | $235 | $6 |
| Montelukast | 24 | $197 | $8 |
| Sulfamethoxazole-Trimethoprim | 25 | $111 | $4 |
| Mupirocin | 14 | $108 | $8 |
| Fluconazole | 16 | $58 | $4 |
| Zolpidem | 11 | $25 | $2 |
Year by year
| 2024 | 510 | 214 | None | None | $43,955 |
| 2023 | 376 | 173 | None | None | $25,279 |
| 2022 | 330 | 149 | 0% (0) | None | $30,385 |
| 2021 | 404 | 162 | None | None | $52,776 |
| 2020 | 377 | 131 | None | 18% | $41,386 |
| 2019 | 477 | 181 | None | 16% | $45,883 |
| 2018 | 308 | 133 | None | 5% | $19,264 |
| 2017 | 417 | 147 | None | 12% | $37,369 |
| 2016 | 727 | 181 | 2% (11) | 20% | $75,420 |
| 2015 | 890 | 188 | 2% (21) | 24% | $79,032 |
| 2014 | 914 | 206 | 3% (27) | 31% | $99,898 |
| 2013 | 1,130 | 208 | 2% (25) | 37% | $130,949 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Mometasone Furoate | 13 | $1,475 | $113 |
| Doxycycline Hyclate | 50 | $1,232 | $25 |
| Ipratropium | 33 | $1,155 | $35 |
| Azelastine | 17 | $707 | $42 |
| Montelukast | 31 | $631 | $20 |
| Ciprofloxacin | 16 | $432 | $27 |
| Methylprednisolone | 43 | $375 | $9 |
| Amoxicillin-Clavulanate Potass | 26 | $336 | $13 |
| Prednisone | 25 | $215 | $9 |
| Azithromycin | 19 | $209 | $11 |
| Mupirocin | 12 | $123 | $10 |
| Sulfamethoxazole-Trimethoprim | 14 | $105 | $7 |
2022: 10 drugs
| Ciprofloxacin-Dexamethasone | 12 | $3,816 | $318 |
| Budesonide | 12 | $1,488 | $124 |
| Ipratropium | 27 | $1,260 | $47 |
| Azelastine | 28 | $1,057 | $38 |
| Doxycycline Hyclate | 32 | $751 | $23 |
| Methylprednisolone | 50 | $556 | $11 |
| Desloratadine | 13 | $533 | $41 |
| Montelukast | 34 | $472 | $14 |
| Prednisone | 16 | $103 | $6 |
| Amoxicillin-Clavulanate Potass | 12 | $98 | $8 |
2021: 9 drugs
| Azelastine | 60 | $2,729 | $45 |
| Ipratropium | 35 | $2,518 | $72 |
| Montelukast | 43 | $726 | $17 |
| Doxycycline Hyclate | 20 | $460 | $23 |
| Methylprednisolone | 43 | $412 | $10 |
| Amoxicillin-Clavulanate Potass | 28 | $376 | $13 |
| Fluticasone Propionate | 12 | $276 | $23 |
| Mupirocin | 15 | $234 | $16 |
| Azithromycin | 13 | $85 | $7 |
2020: 13 drugs
| Ciprodex | 17 | $6,363 | $374 |
| Azelastine | 34 | $1,641 | $48 |
| Ipratropium | 15 | $1,563 | $104 |
| Montelukast | 31 | $632 | $20 |
| Doxycycline Hyclate | 14 | $472 | $34 |
| Clarithromycin | 12 | $444 | $37 |
| Amoxicillin-Clavulanate Potass | 28 | $398 | $14 |
| Fluticasone Propionate | 18 | $370 | $21 |
| Methylprednisolone | 32 | $324 | $10 |
| Mupirocin | 22 | $316 | $14 |
| Prednisone | 13 | $107 | $8 |
| Azithromycin | 11 | $96 | $9 |
| Sulfamethoxazole-Trimethoprim | 19 | $77 | $4 |
2019: 13 drugs
| Xhance | 17 | $10,209 | $601 |
| Ciprodex | 22 | $8,905 | $405 |
| Azelastine | 47 | $2,322 | $49 |
| Ipratropium | 29 | $1,379 | $48 |
| Montelukast | 44 | $784 | $18 |
| Methylprednisolone | 55 | $680 | $12 |
| Amoxicillin-Clavulanate Potass | 29 | $415 | $14 |
| Doxycycline Hyclate | 19 | $370 | $19 |
| Mupirocin | 28 | $352 | $13 |
| Fluticasone Propionate | 14 | $243 | $17 |
| Prednisone | 23 | $173 | $8 |
| Sulfamethoxazole-Trimethoprim | 28 | $159 | $6 |
| Azithromycin | 14 | $117 | $8 |
2018: 11 drugs
| Azelastine | 35 | $3,115 | $89 |
| Mometasone Furoate | 13 | $1,370 | $105 |
| Ipratropium | 23 | $666 | $29 |
| Montelukast | 26 | $612 | $24 |
| Methylprednisolone | 36 | $460 | $13 |
| Fluticasone Propionate | 15 | $319 | $21 |
| Amoxicillin-Clavulanate Potass | 24 | $319 | $13 |
| Mupirocin | 20 | $301 | $15 |
| Prednisone | 19 | $180 | $9 |
| Sulfamethoxazole-Trimethoprim | 22 | $168 | $8 |
| Azithromycin | 14 | $90 | $6 |
2017: 11 drugs
| Azelastine | 80 | $5,420 | $68 |
| Mometasone Furoate | 11 | $2,863 | $260 |
| Dymista | 11 | $2,002 | $182 |
| Montelukast | 59 | $1,198 | $20 |
| Fluticasone Propionate | 30 | $731 | $24 |
| Ipratropium | 12 | $578 | $48 |
| Methylprednisolone | 34 | $432 | $13 |
| Amoxicillin-Clavulanate Potass | 24 | $324 | $14 |
| Prednisone | 22 | $240 | $11 |
| Ciprofloxacin | 13 | $138 | $11 |
| Sulfamethoxazole-Trimethoprim | 16 | $68 | $4 |
2016: 18 drugs
| Nasonex | 28 | $13,070 | $467 |
| Budesonide | 15 | $10,930 | $729 |
| Azelastine | 111 | $8,898 | $80 |
| Ciprodex | 14 | $5,294 | $378 |
| Mometasone Furoate | 12 | $5,005 | $417 |
| Qnasl | 14 | $3,625 | $259 |
| Dymista | 14 | $3,427 | $245 |
| Clarinex | 14 | $2,822 | $202 |
| Montelukast | 129 | $2,581 | $20 |
| Omnaris | 11 | $2,573 | $234 |
| Fluticasone Propionate | 61 | $1,168 | $19 |
| Ciprofloxacin | 30 | $713 | $24 |
| Methylprednisolone | 37 | $603 | $16 |
| Amoxicillin-Clavulanate Potass | 31 | $448 | $14 |
| Mupirocin | 52 | $396 | $8 |
| Prednisone | 26 | $218 | $8 |
| Sulfamethoxazole-Trimethoprim | 23 | $194 | $8 |
| Azithromycin | 17 | $152 | $9 |
2015: 20 drugs
| Nasonex | 33 | $15,077 | $457 |
| Ciprodex | 41 | $12,863 | $314 |
| Azelastine | 122 | $11,237 | $92 |
| Budesonide | 16 | $8,498 | $531 |
| Montelukast | 187 | $3,894 | $21 |
| Omnaris | 16 | $3,065 | $192 |
| Clarinex | 14 | $2,700 | $193 |
| Dymista | 11 | $2,640 | $240 |
| Qnasl | 11 | $1,895 | $172 |
| Fluticasone Propionate | 99 | $1,453 | $15 |
| Clarithromycin | 14 | $723 | $52 |
| Methylprednisolone | 35 | $675 | $19 |
| Amoxicillin-Clavulanate Potass | 40 | $673 | $17 |
| Ipratropium | 11 | $592 | $54 |
| Ciprofloxacin | 21 | $516 | $25 |
| Sulfamethoxazole-Trimethoprim | 39 | $286 | $7 |
| Mupirocin | 21 | $279 | $13 |
| Levofloxacin | 12 | $231 | $19 |
| Prednisone | 27 | $216 | $8 |
| Fluconazole | 17 | $198 | $12 |
2014: 19 drugs
| Nasonex | 54 | $19,064 | $353 |
| Ciprodex | 61 | $16,489 | $270 |
| Budesonide | 25 | $11,084 | $443 |
| Azelastine | 80 | $7,607 | $95 |
| Astepro | 26 | $5,815 | $224 |
| Montelukast | 195 | $5,444 | $28 |
| Patanase | 16 | $5,225 | $327 |
| Dymista | 22 | $4,077 | $185 |
| Clarinex | 13 | $2,331 | $179 |
| Clarithromycin | 13 | $2,317 | $178 |
| Fluticasone Propionate | 112 | $2,280 | $20 |
| Qnasl | 14 | $1,965 | $140 |
| Omnaris | 12 | $1,925 | $160 |
| Methylprednisolone | 33 | $824 | $25 |
| Ciprofloxacin | 23 | $585 | $25 |
| Amox Tr-Potassium Clavulanate | 26 | $432 | $17 |
| Hydrocodone-Acetaminophen | 14 | $374 | $27 |
| Sulfamethoxazole-Trimethoprim | 41 | $325 | $8 |
| Prednisone | 16 | $142 | $9 |
2013: 24 drugs
| Ciprodex | 89 | $24,076 | $271 |
| Nasonex | 82 | $20,652 | $252 |
| Astepro | 85 | $15,338 | $180 |
| Budesonide | 16 | $7,910 | $494 |
| Azelastine | 58 | $6,094 | $105 |
| Montelukast | 162 | $6,012 | $37 |
| Patanase | 17 | $5,020 | $295 |
| Clarithromycin | 31 | $4,283 | $138 |
| Tobramycin-Dexamethasone | 11 | $3,495 | $318 |
| Omnaris | 14 | $3,451 | $247 |
| Dymista | 18 | $2,898 | $161 |
| Fluticasone Propionate | 83 | $2,832 | $34 |
| Clarinex | 12 | $1,954 | $163 |
| Methylprednisolone | 46 | $1,055 | $23 |
| Ipratropium | 13 | $957 | $74 |
| Amox Tr-Potassium Clavulanate | 30 | $682 | $23 |
| Ciprofloxacin | 35 | $456 | $13 |
| Sulfamethoxazole-Trimethoprim | 57 | $396 | $7 |
| Hydrocodone-Acetaminophen | 14 | $350 | $25 |
| Levofloxacin | 20 | $248 | $12 |
| Fluconazole | 15 | $237 | $16 |
| Prednisone | 44 | $180 | $4 |
| Azithromycin | 12 | $131 | $11 |
| Zolpidem | 12 | $51 | $4 |
Money from drug and device companies
$233 in 2025
| 2025 | 3 | 3 | None | $233 |
| 2024 | 2 | 6 | $4,500 | $12,755 |
| 2023 | 1 | 1 | None | $32 |
| 2021 | 3 | 3 | None | $260 |
| 2020 | 2 | 2 | $950 | $962 |
| 2019 | 4 | 7 | $1,650 | $1,819 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | None | $118 | 1 payment
|
| Genzyme | Wayrilz | $96 | 1 payment
|
| Neurent Medical | Neuromark System | $19 | 1 payment
|
See all 3 published payments
| Neurent Medical | Meals · 2025-07-24 | Neuromark System | $19 |
| GlaxoSmithKline | Meals · 2025-07-11 | None | $118 |
| Genzyme | Meals · 2025-02-07 | Wayrilz | $96 |
See earlier years (2024, 2023, 2021, 2020, 2019)
2024: $12,755
| Neurent Medical | Neuromark Device | $12,741 | 5 payments
|
| Regeneron Healthcare Solutions | Dupixent | $15 | 1 payment
|
2023: $32
| Neurent Medical | Neuromark Device | $32 | 1 payment
|
2021: $260
| Medtronic | Stealthstation | $123 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $71 | 1 payment
|
| GlaxoSmithKline | None | $66 | 1 payment
|
2020: $962
| Medtronic USA | Straightshot | $950 | 1 payment
|
| GlaxoSmithKline | Anoro Ellipta | $12 | 1 payment
|
2019: $1,819
| Genzyme | Dupixent | $1,758 | 4 payments
|
| Acclarent | Trudi | $31 | 1 payment
|
| OptiNose US | Xhance | $16 | 1 payment
|
| Sanofi-Aventis U.S. | No Product Discussed | $14 | 1 payment
|
Checkups this office reported
16 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 87.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 87%That's most of the people this applied to. | 982 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 51%That's more than half. | 296 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 4%That's few of the people this applied to. Better on this measure. | 83 |
| Breast cancer screeningEligible women who got a mammogram | 66%That's more than half. | 385 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 28%That's less than half. | 424 |
| Checked for fall riskOlder patients screened for fall risk | 2%That's few of the people this applied to. | 699 |
| Colon cancer screeningEligible adults who got a colon cancer test | 48%That's less than half. | 902 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 1%That's few of the people this applied to. | 1,529 |
See the other 8 measures
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 2%That's few of the people this applied to. | 62 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 95%That's most of the people this applied to. Worse on this measure. | 62 |
| HIV screeningEligible patients who were screened for HIV | 15%That's few of the people this applied to. | 1,049 |
| Medications listed in the chartVisits where the current medication list was documented | 63%That's more than half. | 4,113 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 99%That's most of the people this applied to. | 668 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 100%That's most of the people this applied to. | 269 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 69%That's more than half. | 392 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 35%That's less than half. | 1,658 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Exchanges records both ways with other health systems
- Improved the patient portal
- Lets patients read their visit notes
- Reports cases to public health electronically
- Shows lab and imaging costs when ordering tests
- Uses standard treatment protocols
- Exempt from immunization registry reporting
Professional record
- NPI
- 1821182973
- Licence
- CA G77809California G77809: Current · expires 2027-09-30
- Trained
- Stanford University School of Medicine, 1992
- Group
- Bass Medical Group
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 174400000X (174400000X)
- Mailing address
- 1111 Exposition Blvd, Bldg 700, Sacramento, CA, 95815
- NPI first listed
- 2006-10-03
- NPI last updated
- 2015-10-19
This is when the NPI record was last certified, not a medical board exam.